GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Core Points - GENFIT has announced the effective voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Global Select Market, with each ADS representing one ordinary share of the company [1] - The company has filed a Form 15F with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, with the deregistration expected to be effective 90 days after the filing [1] Company Information - GENFIT is a biopharmaceutical company focused on improving the lives of patients with rare and life-threatening liver diseases, with a history of over two decades in liver disease research and development [7] - The company is headquartered in Lille, France, and has additional offices in Paris, Zurich, and Cambridge, MA [11] - GENFIT's R&D portfolio includes therapeutic assets targeting conditions such as Acute on-chronic Liver Failure (ACLF), cholangiocarcinoma (CCA), and urea cycle disorders (UCD) [8] ADS Holder Information - The Bank of New York Mellon serves as the depositary for GENFIT's ADS facility, and the company intends to terminate the Deposit Agreement on or about February 6, 2026 [2] - ADS holders have until February 9, 2026, to surrender their ADSs for the underlying ordinary shares, with applicable fees for cancellation and cable services [3] - After February 9, 2026, the depositary may sell the underlying ordinary shares, and ADS holders must surrender their securities to obtain payment of the sale proceeds, net of expenses [4][6]